Socioeconomic and demographic disparities in rectal cancer treatment.

Authors

null

Vernon Wu

Division of Medical Oncology/Hematology, North Shore University Hospital & Long Island Jewish Medical Center, New Hyde Park, NY

Vernon Wu , Molly Kobritz , Diana Kantarovich , Baho Sidiqi , Leila Tchelebi , Richard L Whelan , Daniel King

Organizations

Division of Medical Oncology/Hematology, North Shore University Hospital & Long Island Jewish Medical Center, New Hyde Park, NY, Division of Surgery, North Shore University Hospital & Long Island Jewish Medical Center, New Hyde Park, NY, Division of Surgery, Lenox Hill Hospital, New York, NY, Division of Radiation Medicine, North Shore University Hospital & Long Island Jewish Medical Center, New Hyde Park, NY, Department of Radiation Medicine, Northwell Health, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Lake Success, NY, Division of Colon and Rectal Surgery, Lenox Hill Hospital, Northwell Health, New York, NY, Northwell Health Cancer Institute and Feinstein Institute of Research, Lake Success, NY

Research Funding

No funding received
None.

Background: Early treatment (tx) improves survival in rectal cancer (ca). We explored whether socioeconomic and demographic attributes are associated with time to tx initiation for rectal ca patients (pts) in New York's largest and most diverse healthcare system. Methods: 283 rectal ca pts were identified from three multidisciplinary tumor boards from 2019-2022. Time to tx was calculated as time from biopsy to first tx (surgery, chemotherapy, or radiation). Social work assistance was defined as an intervention by a social worker for home care, housing, or transportation assistance. Reasons for tx delay were assessed from physician and social work notes. Results: Median time to tx for all pts was 41 days. Time to tx was longer for Black/African American (BAA) (56.5 days; p < 0.001) and Medicare only (46.5 days; p = 0.005) pts. No differences were seen in time to tx for all pts when stratified by first tx modality (surgery, chemotherapy, or radiation). In a univariable linear regression, BAA pts (vs Asian or White; p < 0.001), Medicare only pts (vs Medicaid, Medicare with Supplemental, or Commercial Insurance; p = 0.001), and pts requesting social work assistance (p = 0.001) predicted longer time to tx. Employed pts (vs unemployed or retired; p = 0.034) predicted shorter time to tx. In a multivariable model, BAA (p = 0.013), Medicare (p = 0.022), and social work assistance (p = 0.029) predicted longer time to tx. The most common reasons identified for tx delay in BAA and Medicare pts were hospitalization during diagnosis (9%), evaluation of metastatic disease (9%), and tx hesitancy (7%). The odds ratio of being hospitalized during initial workup was 2.8 times higher for BAA than Asian or White pts (p = 0.007). Conclusions: Analysis of time to tx in rectal ca showed a notable delay for BAA pts, Medicare only pts, and pts requesting social work assistance. These findings may empower further studies to assess which factors are causal and to implement interventions that promote equity in timely tx for rectal ca pts. Reasons for tx delay were also not well documented and should be further elucidated.

Time to treatment (days).
UnivariableMultivariable
Coefficient (95% CI)p-valueCoefficient (95% CI)p-value
Age0.10 (-0.11, 0.32)0.345-0.001 (-0.28, 0.27)0.992
Male2.70 (-3.15, 8.56)0.3642.07 (-3.68, 7.81)0.479
Black/African American (vs Asian, White)15.60 (7.42, 23.79)< 0.001*11.49 (2.49, 20.48)0.013*
Hispanic/Latino-1.05 (-19.46, 17.36)0.9112.69 (-15.60, 20.98)0.773
Medicare only (vs Medicaid, Medicare + Supplemental, Commercial)15.19 (6.34, 24.04)0.001*10.87 (1.55, 20.19)0.022*
Non-English Speaker2.04 (-5.78, 9.85)0.6085.61 (-2.32, 13.53)0.165
Married (vs Divorced, Separated, Single, Widowed)-5.09 (-10.89, 0.72)0.086-2.97 (-10.07, 4.14)0.412
Employed (vs Unemployed, Retired)-6.17 (-11.87, -0.48)0.034*-3.26 (-10.27, 3.76)0.361
Social Work Assistance Requested15.67 (6.70, 24.64)0.001*10.49 (1.08, 19.90)0.029*

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2023 ASCO Annual Meeting

Session Type

Publication Only

Session Title

Publication Only: Gastrointestinal Cancer—Colorectal and Anal

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Epidemiology/Outcomes

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr e15512)

DOI

10.1200/JCO.2023.41.16_suppl.e15512

Abstract #

e15512

Abstract Disclosures